Navigation Links
Cytopia Concludes Phase I Oral Trial for Vascular-Disrupting Agent, CYT997
Date:2/5/2009

MELBOURNE, Australia, Feb.5 /PRNewswire/ -- Cytopia Limited (ASX: CYT) has successfully concluded dose-escalation in its oral Phase I study for CYT997, the company's anticancer vascular-disrupting agent (VDA).

The primary objectives of this safety and tolerability study have been achieved. These were to determine the maximum tolerated dose (MTD) and the dose-limiting toxicities (DLTs) for the agent when administered orally in capsule form every two weeks to patients with a diverse range of solid tumors. Safety and tolerability data from this study augments data obtained in the company's first Phase I study where CYT997 was administered intravenously. Together, these studies suggest that the CYT997 is a potent and selective VDA which is well tolerated at biologically efficacious doses and is worthy of further investigation as a novel anticancer agent.

"Cytopia has now demonstrated the broad clinical potential of CYT997 in both intravenous and oral forms," said Mr. Andrew Macdonald, CEO. "The oral activity of CYT997 is a key advantage over most other vascular disrupting agents which are administered intravenously. The oral activity of the agent should markedly improve its clinical and commercial value."

The company has already commenced Phase II studies for the intravenous form of CYT997 and intends to undertake similar efficacy studies for the oral presentation. Investigating the safety and efficacy of metronomic dosing, frequent oral administration at a comparatively low, but biologically effective dose, is of particular interest.

This oral trial was partly funded under the company's $A3 million Commercial Ready grant.

Preliminary trial data

CYT997 was generally well tolerated in this study with a maximum tolerated dose in cancer patients of ca 165 mg/m2. This dose resulted in maximal plasma concentrations some twofold higher than those obse
'/>"/>

SOURCE Cytopia Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cytopia Scientific Presentations on JAK2 Inhibitor Program
2. Cytopia Commences Second Phase II Study in Brain Cancer
3. Cytopia Appoints Study Chairman for JAK2 Clinical Trial
4. Release of Cytopia Abstract for CYT997 Oral Presentation at American Society of Clinical Oncology
5. Cytopia Announces Novel Anti-Cancer Drug Development Collaboration
6. Cytopia Nominates JAK2 Clinical Candidate for Myeloproliferative Disorders
7. Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests
8. Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease
9. Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial
10. Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury
11. FDA Concludes There is No Increased Risk of Cardiac Events for Patients Treated with omeprazole and NEXIUM(R) (esomeprazole magnesium)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 4, 2015 Bayer HealthCare (Bayer) has entered ... (NASDAQ: ISIS ) on ISIS-FXI Rx, an ... of thrombosis. Under the agreement Bayer will further develop ... unmet medical need. As part of the clinical development ... ISIS-FXI Rx in an appropriate patient community. ...
(Date:5/4/2015)...  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) has ... (Bayer) to develop and commercialize ISIS-FXI Rx for ... agreement, Isis is eligible to receive up to $155 ... up-front payment and a $55 million payment upon advancement ... patients with compromised kidney function. Isis is also eligible ...
(Date:5/4/2015)... , May 4, 2015  FireflySci Inc., the newest member of the cuvette manufacturing ... they have turned the cuvette industry on its head by offering scientists amazing support for their ... Photo - http://photos.prnewswire.com/prnh/20150501/213244 ... ... ...
Breaking Medicine Technology:Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 2Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 3Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 2Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 3Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 4Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 5New Cuvette Manufacturer Delivers Fast, Easy Solutions for Even the Hardest Cuvette Experiments 2New Cuvette Manufacturer Delivers Fast, Easy Solutions for Even the Hardest Cuvette Experiments 3
... PharmaTech (Cayman) Inc. (NYSE: WX ), a ... with operations in China and the United States, today ... second quarter of 2011 after the New York Stock ... be Thursday morning, August 11, 2011 Shanghai time). The ...
... RAPIDS, Mich., July 19, 2011 ... rehabilitation and software services that benefit patients, healthcare ... to its multi-state group of outpatient clinics.  Agility ... the Company,s Michigan-based outpatient clinic presence to 23 ...
Cached Medicine Technology:WuXi PharmaTech Schedules Second-Quarter 2011 Earnings Release 2Agility Health Expands National Outpatient Clinic Group with New Michigan Facility 2
(Date:5/4/2015)... May 04, 2015 Leonardo J. Lozada, ... chief physician executive, and William C. Daniel, M.D., Saint ... accepted personal invitations from the Secretary of the Air ... (NSF) at the Air War College, Maxwell Air Force ... influential citizens to senior U.S. and international officers and ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 Each year, the ... to raise funds and awareness for breast cancer. This year, ... will be featured as the entertainment sponsor for the 25th ... on May 9 at the Lenox Square Mall. , The ... race, and to raise $1.2 million. Perimeter Plastic Surgery has ...
(Date:5/4/2015)... TROY Healthcare Solutions is proud to be ... Group (RUG) Conference in Baltimore, MD from May 11 ... Group provides an opportunity for clients to gather to ... , In addition to sponsoring the event, TROY Healthcare ... RUG Conference. Attendees can stop by the TROY booth ...
(Date:5/4/2015)... May 04, 2015 In May of 2010, ... his own life. In the wake of this tragedy, Ty’s ... an organization that exposes the grim reality of bullying and ... platform for Kirk and Laura to share their story and ... from happening to another family — a mission that took ...
(Date:5/4/2015)... Washington, DC (PRWEB) May 04, 2015 ... of Kit Check as a finalist for the EY ... Washington Region. The awards program recognizes entrepreneurs who ... innovation, financial performance and personal commitment to their businesses ... finalist by a panel of independent judges. Award ...
Breaking Medicine News(10 mins):Health News:Saint Luke’s Health System Leadership Selected to Attend National Security Forum 2Health News:Perimeter Plastic Surgery Sponsors 2015 Susan G. Komen Greater Atlanta "Race for the Cure" 2Health News:TROY Healthcare to Exhibit at the Cerner North Atlantic Regional User Group Conference 2Health News:TROY Healthcare to Exhibit at the Cerner North Atlantic Regional User Group Conference 3Health News:WWE Legend "Rowdy" Roddy Piper Teams Up with Stand for the Silent for Timely Anti-Bullying Campaign 2Health News:WWE Legend "Rowdy" Roddy Piper Teams Up with Stand for the Silent for Timely Anti-Bullying Campaign 3Health News:EY announces Kit Check CEO and Co-founder Kevin MacDonald as an EY Entrepreneur Of The Year® 2015 Award finalist in the Greater Washington Region 2
... ten kids think that low-fat crisp, ketchup and bread are a ... ,The study also revealed that one-third of the children between ... in the list and almost 15 pct call pasta vegetable. ... ,"It is clear from our findings that children still need to ...
... vaccine to prevent against Human Cytomegalovirus (hCMV) infection and disease ... , San Diego (UCSD) Skaggs School of Pharmacy and Pharmaceutical ... is the leading viral cause of birth defects and a ... natural immunity doesnt protect against infection by the virus, estimated ...
... central government funds allocated to fight chikungunya last year ... were struggling against the mosquito-borne disease that had ... ,According to data available with the health ministry, ... the worst-affected 16 states to help them contain the ...
... bio-refinery in the Gulf region, which will produce ethanol mainly ... a substitute for petrol and diesel, local newspaper Khaleej Times ... US$28.65 million to build a bio-refinery imported from Brazil in ... according to the report. ,The plant, expected to ...
... was addicted to crystal methamphetamine addiction eight years ago, that she ... Peas' singer revealed that she talked to the basket thinking someone ... ,"I remember thinking somebody was inside of it, going to ... who was crawling in the hamper, the New York Post quoted ...
... The NHS must provide more flexible working, the BMA says today ... embarking on NHS careers outnumber men by almost three to two. ... UK medical schools in 2006 will be surveyed by the BMA ... female, compared with 51% in 1995, when the BMA launched a ...
Cached Medicine News:Health News:New Vaccine for CMV Infection 2Health News:New Vaccine for CMV Infection 3Health News:Chikungunya Spreads as Funds Remain Unspent 2Health News:BMA Calls for Flexible Working as Number of Women Doctors Swell 2
Sebia's Hb AFSC Control provides excellent resolution of normal hemoglobins A & F and abnormal hemoglobins S & C. The control is designed for use with Sebia's Hydragel Hemoglobin and Hydragel Acid He...
The HYRYS™ 2 densitometer is reflective of Sebia's expertise in the development and design of imaging systems and densitometers utilized in the electrophoresis field....
Eliminating the need for any manual pipetting, the HydraPLUS delivers precise micro-volumes of sample directly from primary tubes to four HYDRASYS sample applicators contained in a built-in humidity ...
Inquire...
Medicine Products: